Table 1 Montelukast (MK) as a first line monotherapy in eosinophilic gastroenteritis (EGE)
From: Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review
Authors | Study design | Number of patients, gender (M%), mean age ± SD (years) | Affected segments | Dose, duration | Outcomes: EGE symptoms, tissue eosinophilia (if reported) | Follow-up duration |
|---|---|---|---|---|---|---|
Adult cases | ||||||
Wong et al. [11] | Retrospective case seriesa | One M, – | – | 10 mg daily, 1 month | Symptoms improved, – | 10 months |
Pediatric cases | ||||||
Tien et al. [12] | Retrospective case seriesa | 4, M 75%, 8 ± 4.3b | Stomach and duodenum | 5 mg daily, – | Symptoms resolved in 4/4 cases, Eosinophilia improved 3/3 cases | 12 months |
Selva Kumar et al. [13] | Case report | One F, 12 | Stomach and duodenum | 10 mg daily, 1 month | Symptoms and eosinophilia resolved | – |
Neustrom and Friesen [14]9 | Case report | One F, 13 | Esophagus, stomach and duodenum | 10 mg daily, – | Symptoms resolved, Eosinophilia decreased | 4 months |